Vasoinhibins: endogenous regulators of angiogenesis and vascular function

Trends in Endocrinology and Metabolism

Volumn 17, Issue 8, 2006, Pages 301-307

  Clapp, Carmen ^a   Aranda, Jorge ^a   González, Carmen ^a   Jeziorski, Michael C ^a   de la Escalera, Gonzalo Martínez ^a  

^a CENTRO DE FÍSICA APLICADA Y TECNOLOGÍA AVANZADA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ISOPROTEIN; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; VASOINHIBIN;

ANGIOGENESIS; APOPTOSIS; BLOOD VESSEL FUNCTION; ENDOTHELIUM CELL; FUNCTIONAL PROTEOMICS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; VASODILATATION;

EID: 33748701441     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2006.08.002     Document Type: Review

References (57)

1. Folkman J. Angiogenesis. Annu. Rev. Med. 57 (2006) 1-18
2. Nyberg P., et al. Endogenous inhibitors of angiogenesis. Cancer Res. 65 (2005) 3967-3979
3. Bole-Feysot C., et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr. Rev. 19 (1998) 225-268
4. Macotela Y., et al. Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin. J. Cell Sci. 119 (2006) 1790-1800
5. Piwnica D., et al. Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance. Mol. Endocrinol. 18 (2004) 2522-2542
6. Li C.H. Human growth hormone: 1974-1981. Mol. Cell. Biochem. 46 (1982) 31-41
7. Struman I., et al. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 1246-1251
8. Wroblewski V.J., et al. Proteolysis of human growth hormone by rat thyroid gland in vitro: application of electrospray mass spectrometry and N-terminal sequencing to elucidate a metabolic pathway. Pharm. Res. 10 (1993) 1106-1114
9. Khurana S., et al. Proteolysis of human prolactin: resistance to cathepsin D and formation of a nonangiostatic, C-terminal 16K fragment by thrombin. Endocrinology 140 (1999) 4127-4132
10. Spolaore B., et al. Limited proteolysis of human growth hormone at low pH: isolation, characterization, and complementation of the two biologically relevant fragments 1-44 and 45-191. Biochemistry 43 (2004) 6576-6586
11. Cao Y., et al. Kringle structures and antiangiogenesis. Curr. Med. Chem. Anticancer Agents 2 (2002) 667-681
12. Gebbink M.F., et al. Do antiangiogenic protein fragments have amyloid properties?. Blood 104 (2004) 1601-1605
13. Corbacho A.M., et al. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J. Endocrinol. 173 (2002) 219-238
14. Bentzien F., et al. Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Res. 61 (2001) 7356-7362
15. Kim J., et al. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res. 63 (2003) 386-393
16. Pan H., et al. Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Invest. Ophthalmol. Vis. Sci. 45 (2004) 2413-2419
17. Gonzalez C., et al. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation. Endocrinology 145 (2004) 5714-5722
18. Lee H., et al. Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology 139 (1998) 3696-3703
19. Clapp C., et al. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133 (1993) 1292-1299
20. Martini J.F., et al. The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Mol. Endocrinol. 14 (2000) 1536-1549
21. Dueñas Z., et al. Prolactin in eyes of patients with retinopathy of prematurity: implications for vascular regression. Invest. Ophthalmol. Vis. Sci. 45 (2004) 2049-2055
22. Clapp C., and Weiner R. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology 130 (1992) 1380-1386
23. 2-M phases. Mol. Endocrinol. 19 (2005) 1932-1942
24. D'Angelo G., et al. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the anti-angiogenic factor 16kDa N-terminal fragment of prolactin. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 6374-6378
25. D'Angelo G., et al. 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol. Endocrinol. 13 (1999) 692-704
26. Ziche M., and Morbidelli L. Nitric oxide and angiogenesis. J. Neurooncol. 50 (2000) 139-148
27. Walford G., and Loscalzo J. Nitric oxide in vascular biology. J. Thromb. Haemost. 1 (2003) 2112-2118
28. Lee S.-H., et al. 16-kDa prolactin down-regulates inducible nitric oxide synthase expression through inhibition of the signal transducer and activator of transcription 1/IFN regulatory-pathway. Cancer Res. 65 (2005) 7984-7992
29. Tabruyn S.P. The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB. Mol. Endocrinol. 17 (2003) 1815-1823
30. Cosio G., et al. Hypoxia inhibits expression of prolactin and secretion of cathepsin-D by the GH4C1 pituitary adenoma cell line. Lab. Invest. 83 (2003) 1627-1636
31. Helmlinger G., et al. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin. Cancer Res. 8 (2002) 1284-1291
32. Horseman N.D., et al. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J. 16 (1997) 6926-6935
33. Lin S.C., et al. Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature 364 (1993) 208-213
34. Takeuchi T., et al. Molecular mechanism of growth hormone (GH) deficiency in the spontaneous dwarf rat: detection of abnormal splicing of GH messenger ribonucleic acid by the polymerase chain reaction. Endocrinology 126 (1990) 31-38
35. Zhou Y., et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13215-13220
36. Das A., and McGuire P. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog. Retin. Eye Res. 22 (2003) 721-748
37. Aranda J., et al. Prolactins are natural inhibitors of angiogenesis in the retina. Invest. Ophthalmol. Vis. Sci. 46 (2005) 2947-2953
38. O'Steen W.K., and Sundberg D.K. Patterns of radioactivity in the eyes of rats after injections of iodinated prolactin. Ophthalmic Res. 14 (1982) 54-62
39. Ochoa A., et al. Expression of prolactin gene and secretion of prolactin by rat retinal capillary endothelial cells. Invest. Ophthalmol. Vis. Sci. 42 (2001) 1639-1645
40. Dueñas Z., et al. Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules. Invest. Ophthalmol. Vis. Sci. 40 (1999) 2498-2505
41. Repka M.X., et al. Involution of retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch. Ophthalmol. 118 (2000) 645-649
42. Hylander M.A., et al. Association of human milk feedings with a reduction in retinopathy of prematurity among very low birthweight infants. J. Perinatol. 21 (2001) 356-362
43. Grosvenor C.E., and Whitworth N.S. Accumulation of prolactin in maternal milk and its transfer to circulation of neonate rat: a review. Endocrinol. Exp. 17 (1983) 271-286
44. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
45. Turner H.E., et al. Angiogenesis in endocrine tumors. Endocr. Rev. 24 (2003) 600-632
46. Ueda E., et al. A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone. Endocr. Relat. Cancer 13 (2006) 95-111
47. Merkle C.J., et al. Structural and functional effects of high prolactin levels on injured endothelial cells. Endocrine 13 (2000) 37-46
48. Corbacho A.M., et al. Human umbilical vein endothelial cells express multiple prolactin isoforms. J. Endocrinol. 166 (2000) 53-62
49. Fukuoka H., et al. Heterogeneity of serum and amniotic fluid prolactin in humans. Horm. Res. 35 Suppl. 1 (1991) 58-63
50. Sinha Y.N., and Jacobsen B.P. Human growth hormone (hGH)-(44-191), a reportedly diabetogenic fragment of hGH, circulates in human blood: measurement by radioimmunoassay. J. Clin. Endocrinol. Metab. 78 (1994) 1411-1418
51. Torner L., et al. A 14-kilodalton prolactin-like fragment is secreted by the hypothalamo-neurohypophyseal system of the rat. Endocrinology 136 (1995) 5454-5460
52. Clapp C., et al. The prolactin gene is expressed in the hypothalamic-neurohypophyseal system and the protein is processed into a 14-kDa fragment with activity like 16-kDa prolactin. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 10384-10388
53. Corbacho A.M., et al. Proteolytic cleavage confers nitric oxide synthase inducing activity upon prolactin. J. Biol. Chem. 275 (2000) 13183-13186
54. Warner M.D., et al. Growth hormone and prolactin variants in normal subjects. Relative proportions in morning and afternoon samples. Horm. Metab. Res. 25 (1993) 425-429
55. Lewis U.J., et al. Structure and properties of members of the hGH family: a review. Endocr. J. 47 (2000) S1-S8
56. Teilum K., et al. Solution structure of human prolactin. J. Mol. Biol. 351 (2005) 810-823
57. Walsh S.T., and Kossiakoff A.A. Crystal structure and site 1 binding energetics of human placental lactogen. J. Mol. Biol. 358 (2006) 773-784